T Cell Assays and MIATA: The Essential Minimum for Maximum Impact

Cedrik M. Britten(Johannes Gutenberg University Mainz), Mark M. Davis(Stanford Medicine), Steffen Walter(Universität Ulm), Kunle Odunsi(University of Chicago), Lisa H. Butterfield(Merck & Co., Inc., Rahway, NJ, USA (United States)), Graham Pawelec(Health Sciences North), Cornelis J.M. Melief(ISA Pharmaceuticals (Netherlands)), Michael Kalos(Pillar College), Bart O. Roep(Immune Regulation (United Kingdom)), Jill O’Donnell-Tormey(Cancer Research Institute), Sjoerd H. van der Burg(Leiden University Medical Center), Sylvia Janetzki(Yale University), Guido Ferrari(Duke University), Holden T. Maecker(Stanford University), Christian H. Ottensmeier(Clatterbridge Cancer Centre NHS Foundation Trust), Axel Hoos(GlaxoSmithKline (United States)), Lloyd J. Old(Gynecologic Oncology Group), Mario Roederer(National Institutes of Health), Pedro Romero(TiGenix (Spain)), Christian G. Huber(University of Salzburg), Cécile Gouttefangeas(University of Tübingen), H. I. Levitsky(Johns Hopkins University), Tom H. M. Ottenhoff(Office of Infectious Diseases)
Immunity
July 1, 2012
Cited by 131


Related Papers